PDF(Pubmed)
Abstract：
OBJECTIVE: To explore the relationship between CADM1 expression and sensitivity to TPF-induced chemotherapy in laryngeal squamous cell carcinoma (LSCC) patients, then investigate its potential mechanisms.
METHODS: Differential CADM1 expression was examined in chemotherapy-sensitive and chemotherapy-insensitive LSCC patient samples after TPF-induced chemotherapy using microarray analysis. Receiver operating characteristic (ROC) curve analysis and bioinformatics approaches were used to investigate the diagnostic value of CADM1. Small interfering RNAs (siRNAs) were used to knock down CADM1 expression in an LSCC cell line. Differential CADM1 expression was compared by qRT-PCR assays in 35 LSCC patients treated with chemotherapy, including 20 chemotherapy-sensitive and 15 chemotherapy-insensitive patients.
RESULTS: Public database and primary patient data both suggest that CADM1 mRNA is expressed at lower levels in chemotherapy-insensitive LSCC samples, suggesting its potential usefulness as a biomarker. Knockdown of CADM1 with siRNAs led to decreased sensitivity of LSCC cells to TPF chemotherapy.
CONCLUSIONS: Upregulation of CADM1 expression can alter the sensitivity of LSCC tumors to TPF induction chemotherapy. CADM1 is a possible molecular marker and therapeutic target for induction chemotherapy in LSCC patients.
METHODS: Differential CADM1 expression was examined in chemotherapy-sensitive and chemotherapy-insensitive LSCC patient samples after TPF-induced chemotherapy using microarray analysis. Receiver operating characteristic (ROC) curve analysis and bioinformatics approaches were used to investigate the diagnostic value of CADM1. Small interfering RNAs (siRNAs) were used to knock down CADM1 expression in an LSCC cell line. Differential CADM1 expression was compared by qRT-PCR assays in 35 LSCC patients treated with chemotherapy, including 20 chemotherapy-sensitive and 15 chemotherapy-insensitive patients.
RESULTS: Public database and primary patient data both suggest that CADM1 mRNA is expressed at lower levels in chemotherapy-insensitive LSCC samples, suggesting its potential usefulness as a biomarker. Knockdown of CADM1 with siRNAs led to decreased sensitivity of LSCC cells to TPF chemotherapy.
CONCLUSIONS: Upregulation of CADM1 expression can alter the sensitivity of LSCC tumors to TPF induction chemotherapy. CADM1 is a possible molecular marker and therapeutic target for induction chemotherapy in LSCC patients.
摘要：
目的：探讨CADM1表达与喉鳞状细胞癌（LSCC）患者TPF诱导化疗敏感性的关系。然后研究其潜在机制。
方法：使用微阵列分析在TPF诱导的化疗后，在化疗敏感和化疗不敏感的LSCC患者样本中检测CADM1的差异表达。采用受试者工作特征（ROC）曲线分析和生物信息学方法探讨CADM1的诊断价值。小干扰RNA(siRNA)用于敲低LSCC细胞系中的CADM1表达。通过qRT-PCR分析比较了35例接受化疗的LSCC患者的差异CADM1表达，包括20例化疗敏感患者和15例化疗不敏感患者。
结果：公共数据库和主要患者数据均表明，在化疗不敏感的LSCC样本中，CADM1mRNA表达水平较低，表明其作为生物标志物的潜在用途。用siRNA敲除CADM1导致LSCC细胞对TPF化疗的敏感性降低。
结论：上调CADM1表达可改变LSCC肿瘤对TPF诱导化疗的敏感性。CADM1可能是LSCC患者诱导化疗的分子标志物和治疗靶点。
方法：使用微阵列分析在TPF诱导的化疗后，在化疗敏感和化疗不敏感的LSCC患者样本中检测CADM1的差异表达。采用受试者工作特征（ROC）曲线分析和生物信息学方法探讨CADM1的诊断价值。小干扰RNA(siRNA)用于敲低LSCC细胞系中的CADM1表达。通过qRT-PCR分析比较了35例接受化疗的LSCC患者的差异CADM1表达，包括20例化疗敏感患者和15例化疗不敏感患者。
结果：公共数据库和主要患者数据均表明，在化疗不敏感的LSCC样本中，CADM1mRNA表达水平较低，表明其作为生物标志物的潜在用途。用siRNA敲除CADM1导致LSCC细胞对TPF化疗的敏感性降低。
结论：上调CADM1表达可改变LSCC肿瘤对TPF诱导化疗的敏感性。CADM1可能是LSCC患者诱导化疗的分子标志物和治疗靶点。
